Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops

Halozyme Therapeutics (HALO) shares dropped 4.28% to $117.69 on November 6, despite reporting a 39% revenue increase to $493 million and slightly higher 2026 guidance. Royalty revenue rose 44% to $341 million, and GAAP EPS increased to $2.01. The company's 2026 revenue guidance was raised to $1.860B-$1.925B, with non-GAAP EPS now $8.75-$9.05.

FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO for head and neck cancer treatment. The drug, co-formulated with Halozyme's ENHANZE technology, targets specific receptors. Halozyme (HALO) licenses its technology to multiple pharmaceutical companies. The therapy was previously approved for lung cancer.

Halozyme (HALO) announced FDA approval for RYBREVANT FASPRO, co-formulated with its ENHANZE technology, for treating advanced head and neck cancer. The approval expands the drug's use beyond lung cancer, targeting a high unmet need. Halozyme's CEO highlighted the technology's role in improving patient treatment options. Johnson & Johnson, which markets the drug, issued a separate press release.

Halozyme Therapeutics (HALO) shares fell 8.1% in pre-market trading after its Q3 2026 earnings report. The company beat estimates with $2.39 EPS and $493M revenue, but guidance raised to $1.86B-$1.925B revenue and $8.75-$9.05 EPS only slightly exceeded expectations. The stock had risen 11.9% ahead of the report, and the broader market's decline added to the pressure.

Halozyme reported Q3 2026 revenue of $493M, up 39% YoY, driven by royalty revenue growth. The company raised full-year guidance and announced expansions with partners like Argenx, Incyte, and Johnson & Johnson, adding new targets and potential revenue streams. Key products like DARZALEX subcutaneous, VYVGART Hytrulo, and Phesgo showed strong performance, with significant conversion rates and growth prospects.

Halozyme (HALO) raised its 2026 revenue and earnings guidance, citing higher royalty expectations. The company reported $1.08B in cash and $3.3B in long-term debt, completing $400M in share repurchases. Partners advanced ENHANZE programs, and Halozyme expects 13 new products by 2032. The company is also developing Hypercon and Aerocon technologies. A Dutch court ruled in Halozyme's favor in a patent dispute with Merck.